key: cord-0810522-rkfth16d authors: Echavarria, Marcela; Reyes, Noelia S.; Rodriguez, Pamela E.; Ypas, Martin; Ricarte, Carmen; Rodriguez, María P.; Perez, Matias G.; Seoane, Alejandro; Martinez, Alfredo; Videla, Cristina; Stryjewski, Martin E.; Carballal, Guadalupe title: Self‐collected saliva for SARS‐CoV‐2 detection: A prospective study in the emergency room date: 2021-02-23 journal: J Med Virol DOI: 10.1002/jmv.26839 sha: 34ad86a891bf668c1649833ccdc7a955ac788a2f doc_id: 810522 cord_uid: rkfth16d Current diagnostic standards involve severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) detection in nasopharyngeal swabs (NPS), but saliva is an attractive and noninvasive option for diagnosis. The objectives were to determine the performance of saliva in comparison with NPS for detecting SARS‐CoV‐2 and to compare the optimized home brew reverse‐transcription polymerase chain reaction (RT‐PCR) with a commercial RT‐PCR. Paired NPS and saliva specimens were prospectively collected and tested by RT‐PCR from patients presenting at an emergency room with signs and symptoms compatible with coronavirus disease‐2019. A total of 348 samples from 174 patients were tested by RT‐PCR assays. Among 174 patients with symptoms, 63 (36%) were SARS‐CoV‐2 positive in NPS using the optimized home‐brew PCR. Of these 63 patients, 61 (98%) were also positive in saliva. An additional positive SARS‐CoV‐2 saliva was detected in a patient with pneumonia. Kappa Cohen's coefficient agreement between NPS and saliva was 0.96 (95% confidence interval [CI], 0.90–0.99). Median Ct values in NPS versus saliva were 18.88 (interquartile range [IQR], 15.60–23.58; range, 11.97–38.10) versus 26.10 (IQR, 22.75–30.06; range, 13.78–39.22), respectively (p < .0001). The optimized home‐brew RT‐PCR demonstrated higher analytical and clinical sensitivity compared with the commercial RT‐PCR assay. A high sensitivity (98%) and agreement (kappa 0.96) in saliva samples compared to NPS was demonstrated when using an optimized home‐brew PCR even when the viral load in saliva was lower than in NPS. This noninvasive sample is easy to collect, requires less consumable and avoids discomfort to patients. Importantly, self‐collection of saliva can diminish exposure to healthcare personnel. The number of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease-2019 remains increasing during the ongoing pandemic. A crucial strategy for controlling transmission relies on expanding diagnosis. The current diagnostic standard involves detection of SARS-CoV-2 by reverse-transcription polymerase chain reaction (RT-PCR) using nasopharyngeal swabs (NPS). However, NPS are associated with patient's discomfort or complications-such as iatrogenic cerebrospinal fluid leak-as well as an increasing healthcare worker's exposure to SARS-CoV-2. 1, 2 Saliva is an attractive and noninvasive option for diagnosing SARS-CoV-2 and sampling enables self-collection without causing discomfort or pain. In addition, self-collection of saliva can reduce the exposure to healthcare personnel by avoiding cough, sneezing, and/or aerosolization during sampling. Furthermore, saliva testing requires less consumables, offering a significant benefit when there is shortage of supplies. 3 The value of using saliva for SARS-CoV-2 detection has been variable between different studies. Such variability may be related to the type of collection, processing, detection techniques, and/or PCR assays. 4 The objectives of this study were to determine the performance of saliva in comparison to NPS for detecting SARS-CoV-2 and to compare our optimized home brew RT-PCR with a commercial RT-PCR. Paired NPS and saliva were prospectively collected from patients presenting at the emergency room (ER) in CEMIC University Hospital from August to September 2020. Patients more than or equal to 18 years old with signs or symptoms potentially due to COVID-19 were invited to participate in the study. This study was approved by the Ethics Committee of CEMIC (Protocol: 1298/20). Signs or symptoms of COVID-19 included fever (>37.5°C), throat, abdominal or chest pain, rhinorrhea, cough, dyspnea, myalgias, headache, anosmia, or dysgeusia. All patients were evaluated by a trained ER physician. NPS were obtained and placed in a sterile tube with 2 ml viral transport media (Minimun Essential Medium; Gibco); L-Glutamine 200 mM; HEPES 1 N; Bovine Albumin 5%; Sigma; Sodium Bicarbonate 7.5%; Penicillin, Streptomycin, and Amphotericin; pH = 7.2). Patients were also instructed to collect saliva by themselves in a plastic sterile container without any transport media. Both NPS and saliva samples were transported at room temperature to the laboratory within 2 h of sample collection. NPS collected in 2 ml of viral transport medium were vortexed in a biosafety cabinet and an aliquot was used for nucleic acid extraction. Saliva samples were conserved at 4°C until processed in a biosafety cabinet within 48 h from arrival. Viscous saliva samples were mechanically disrupted by adding 500 µl viral transport medium. Nucleic acid was extracted from 100 µl and eluted in 15 µl using manual columns (Quick-RNA™ Viral Kit, Zymo Research Corp.) following manufacturer's recommendation. An in-house one-step realtime RT-PCR assay targeting the E gene of SARS-CoV-2 was performed. 5 Optimization of this assay was done to achieve a higher analytical sensitivity. Specifically, magnesium final concentration was increased to 3.8 mM and cycling conditions were modified into three PCR steps. Such steps included an initial transcription stage (10 min at 55°C), followed by 2 min at 95°C, and subsequently by 45 cycles (95°C for 15 s, 55°C for 30 s, and 72°C for 15 s). Quality control amplification was confirmed by testing the human RNAse P gene. This optimized PCR assay was compared to a commercial RT-PCR that amplifies SARS-CoV-2 E gene and S gene and includes an in- A total of 174 patients with signs or symptoms consistent with COVID-19 were enrolled. Clinical and demographic characteristics of these patients are described in Table 1 In contrast, some studies have shown a lower sensitivity in saliva compared with NPS. 10 Saliva collection and/or processing as well as sensitivity of the PCR assay may play a role in such lower performances. 10, 11 In fact, the need of optimizing saliva collection and processing has been previously suggested. 12 In this study, saliva collection without any transport media or any nucleic acid stabilization proved to be adequate to achieve a high detection rate and sensitivity. Furthermore, optimization of the in-house RT-PCR assay increased the limit of detection compared with previous reports and to the commercial assay also evaluated in this study. 5 As viral loads in saliva can be lower than in NPS, optimized and sensitive assays are recommended. Discrepant results between both PCR assays were observed in saliva samples when Ct values were higher than 28 and occurred in NPS when Ct values were higher than 35. These results underscore the importance of highly sensitive assays for accurate diagnosis. One limitation of this study is that patients were relatively young and with mild symptoms. Saliva production may be diminished in older and/or less collaborative patients. Therefore, the performance of this test in other populations (e.g., older and sicker) will be further investigated. In conclusion, our study demonstrates that testing self-collected saliva can be as sensitive as the NPS for diagnosing COVID-19 among ambulatory patients. Saliva collection and processing is important to achieve adequate diagnosis. The use of pure saliva without transport media or stabilizators showed no RNA degradation. This noninvasive sample is easy to collect, requires less consumables, and avoids discomfort to patients. In addition, selfcollection of saliva can diminish exposure to SARS-CoV-2 in healthcare personnel. Further studies are needed to evaluate the role of saliva testing in other populations and settings. Marcela Echavarría and an internal fund from CEMIC and Fundación "Norberto Quirno Martin Stryjewski is a consultant to Basilea, a speaker for Pfizer and principal investigator in Argentina for NIH grant UM1AI104681. The Conceptualization, Funding Acquisition, Investigation, Project Administration, Resources, Visualization, Writing -Original Draft Preparation Data Curation Data Curation, Formal Analysis, Methodology, Writing -Original Draft Preparation, Writing -Review & Editing Resources, Writing -Review & Editing; Cristina Videla: Resources, Writing -Review & Editing Conceptualization, Formal Analysis, Writing -Original Draft Preparation, Writing -Review & Editing Guadalupe Carballal: Conceptualization, Writing -Original Draft Preparation, Writing -Review & Editing. PEER REVIEW The peer review history for this article is SARS-CoV-2 and saliva as a diagnostic tool: A real possibility. Pesqui Bras Odontopediatria Clin Integr Cerebrospinal fluid leak after nasal swab testing for coronavirus disease 2019 Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study Saliva as a noninvasive specimen for detection of SARS-CoV-2 Diagnostic detection of 2019-nCoV by real-time RT-RCR Comparing nasopharyngeal swab and early morning saliva for the identification of SARS-CoV-2 Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs Saliva is a reliable tool to detect SARS-CoV-2 _ Elsevier Enhanced Reader.pdf High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa Consistent detection of 2019 novel coronavirus in saliva The effect of sample site, illness duration, and the presence of pneumonia on the detection of SARS-CoV-2 by real-time reverse transcription PCR Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients Self-collected saliva for SARS-CoV-2 detection: A prospective study in the emergency room We are very grateful to all patients and to Fernando Olivera, Carlos The data that support the findings of this study are available from the corresponding author upon reasonable request. https://orcid.org/0000-0001-6987-8397